Khosla Ventures
Khosla Ventures is a California-based venture capital firm founded in 2004 by Vinod Khosla. It provides capital and strategic guidance to startups across stages, focusing on technology-driven companies in areas such as artificial intelligence, climate and sustainability, enterprise software and services, fintech, digital health, medical technology and diagnostics, therapeutics, consumer products, and frontier technologies. The firm backs bold ventures with the potential to disrupt markets and improve lives, supporting companies from early to growth stages and working closely with entrepreneurs to apply science, technology and innovative business models. While primarily investing in North American technology companies, Khosla Ventures pursues opportunities globally and emphasizes experimentation and impact alongside financial returns. The firm also maintains related impact initiatives that support entrepreneurs addressing socio-economic challenges in emerging markets.
Top Sectors
Top Regions
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Clinical Trials
Tempero Bio
Series B in 2025
Tempero Bio is a clinical-stage biopharmaceutical company developing treatments for substance use disorders. Its primary focus is on creating transformative therapies, including an orally available metabotropic glutamate receptor (mGluR5) negative allosteric modulator (NAM), designed to regulate neural signaling and treat conditions such as cocaine and alcohol use disorders.
Clear Labs
Series D in 2025
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Viome Life Sciences
Series D in 2024
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Karius
Series C in 2024
Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.
Rubedo Life Sciences
Series A in 2024
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.
Relation Therapeutics
Seed Round in 2024
Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.
Siolta Therapeutics
Series C in 2024
Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.
Moonwalk Biosciences
Series A in 2024
Moonwalk Biosciences is a genomic medicine startup focused on developing precision epigenetic therapeutics. The company specializes in creating a profiling and engineering technology platform that leverages advanced artificial intelligence predictions to offer a comprehensive view of the epigenome in both health and disease states. This innovative approach aims to revolutionize therapy discovery and development, enabling healthcare providers to reprogram cells back to their healthy state.
Encellin
Series A in 2023
Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.
Eligo Bioscience
Series B in 2023
Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.
Vivodyne
Seed Round in 2023
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies. Its platform cultures human tissues in labs for realistic preclinical drug testing, using advanced AI to accelerate the creation of safe and effective therapeutics.
Rejuvenation Technologies
Seed Round in 2023
Founded in 2016, Rejuvenation Technologies is a biotechnology company based in Mountain View, California. It specializes in developing nucleoside-modified TERT mRNA to safely extend telomeres for human health extension.
Viome Life Sciences
Series C in 2023
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Surge Therapeutics
Series B in 2023
SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.
Tachyon Therapeutics
Series A in 2023
Tachyon Therapeutics develops innovative compounds to enhance cancer treatments. It is currently conducting Phase 1 clinical trials to evaluate the safety and efficacy of its lead compound, TACH101.
Surge Therapeutics
Series A in 2022
SURGE Therapeutics is a biotechnology company focused on enhancing cancer treatment outcomes through innovative immunotherapy solutions. It has developed a proprietary injectable biodegradable hydrogel designed to deliver cancer therapeutics in a prolonged and localized manner. This technology enables targeted release of immunotherapy agents at the surgical site following tumor resection, allowing for more effective treatment administration. By optimizing the timing and location of drug delivery, SURGE Therapeutics aims to improve patient survival rates and minimize systemic side effects, representing a significant advancement in the field of cancer care.
Viome Life Sciences
Series C in 2022
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Faeth Therapeutics
Series A in 2022
Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.
Relation Therapeutics
Seed Round in 2022
Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.
Ultima Genomics
Venture Round in 2022
Ultima Genomics is a biotechnology company established in 2016 and headquartered in Newark, California. It specializes in genome-scale sequencing technology, focusing on providing analytical services to various enterprises. By employing an open substrate, Ultima Genomics creates a vast, low-cost reaction surface that facilitates billions of reads without relying on expensive flow cells or complex fluidic systems. The company utilizes specialized sequencing hardware combined with machine learning techniques to ensure reproducible and accurate results. This innovative approach enables clients to obtain genomic reports at scale, enhancing the speed and efficiency of sequencing while significantly reducing costs. Ultima Genomics aims to harness the potential of genomic information to drive advancements in biology and improve human health.
Mirvie
Series B in 2022
Mirvie is a biotechnology company specializing in precise, non-invasive diagnostic tests for maternal-fetal health. Founded in 2018, the company aims to enhance pregnancy safety by providing actionable insights to families and enabling early intervention for potential complications.
Scipher Medicine
Series D in 2022
Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.
Cellino
Series A in 2022
Cellino develops scalable, automated biomanufacturing systems for personalized cell therapies based on induced pluripotent stem cells (iPSCs). The company aims to enable potentially curative, patient-specific treatments by producing autologous iPSCs at scale and applying AI-guided, image-driven laser processing and robotics to remove unwanted cells. By integrating image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to enhance precision, efficiency, and scalability in optical bioprocessing, accelerating the development of regenerative therapies for chronic degenerative diseases such as vision loss and Parkinson's disease.
Faeth Therapeutics
Seed Round in 2022
Faeth Therapeutics is a healthcare company dedicated to enhancing cancer treatment through a deep understanding of the relationship between dietary nutrients and tumor growth. By aligning specific diets with tumor genotypes and treatment regimens, Faeth aims to limit the energy and resources that tumors need to proliferate, thereby improving patient outcomes in cancer therapy. Founded by leading researchers and clinicians, the company seeks to translate significant discoveries from cancer research laboratories into effective clinical practices, focusing on evidence-based approaches to optimize treatment strategies for cancer patients.
Fountain Therapeutics
Series A in 2021
Founded in 2018, Fountain Therapeutics develops cellular model-based therapeutics targeting age-related diseases. It employs an AI-driven platform for identifying novel targets and potential treatments.
Viome Life Sciences
Series C in 2021
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Lightship
Series C in 2021
Founded in 2018, Lightship aims to enhance health equity globally by transforming clinical trials. It combines digital health innovations, technology, remote care, and high-quality clinical research to make studies more accessible and offer choices, keeping patients at the core of its work.
Encellin
Seed Round in 2021
Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.
Deep Genomics
Series C in 2021
Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.
Ellipsis Health
Series A in 2021
Founded in 2013, Ellipsis Health is a technology company that uses artificial intelligence to improve behavioral health. It analyzes patient speech and clinical data to predict health outcomes and provide real-time assessments for conditions like depression.
Clear Labs
Series C in 2021
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Pendulum Therapeutics
Series C in 2021
Pendulum Therapeutics is a biotechnology company specializing in microbiome-targeted therapies. Founded in 2013 by experts in microbiology, biochemistry, computational science, and clinical research, the company develops evidence-based medical probiotics to manage chronic illnesses, with a focus on type 2 diabetes. Its flagship product, Pendulum Glucose Control, has demonstrated efficacy in lowering blood sugar spikes and reducing A1C levels in clinical trials.
Scipher Medicine
Series C in 2021
Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.
Cellino
Seed Round in 2021
Cellino develops scalable, automated biomanufacturing systems for personalized cell therapies based on induced pluripotent stem cells (iPSCs). The company aims to enable potentially curative, patient-specific treatments by producing autologous iPSCs at scale and applying AI-guided, image-driven laser processing and robotics to remove unwanted cells. By integrating image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to enhance precision, efficiency, and scalability in optical bioprocessing, accelerating the development of regenerative therapies for chronic degenerative diseases such as vision loss and Parkinson's disease.
Rubedo Life Sciences
Seed Round in 2020
Rubedo Life Sciences, Inc. is a biopharmaceutical company based in Sunnyvale, California, focused on developing innovative therapies that target senescent cells implicated in age-related diseases. Established in 2018, the company utilizes its proprietary ALEMBIC drug discovery platform to create a pipeline of therapeutic candidates. These candidates are designed to selectively address senescent cells, as well as pro-inflammatory and pro-fibrotic cell populations that contribute to various chronic conditions, including pulmonary, dermatological, oncological, neurodegenerative, and fibrotic diseases. Rubedo's leadership team comprises industry experts with significant experience in drug development and commercialization across both large pharmaceutical companies and biotech firms.
Siolta Therapeutics
Series B in 2020
Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.
Focal Medical
Series A in 2020
Focal Medical is a biopharmaceutical company focused on developing targeted therapeutic delivery systems for cancer. It leverages an innovative and patent-protected platform to create therapies that actively direct chemotherapeutics to tumor sites, aiming to improve efficacy and reduce systemic exposure. The lead program targets pancreatic cancer by delivering gemcitabine directly to the pancreas through non-circulatory pathways. The company also develops drug-delivery technologies for solid tumors that are difficult to treat with systemic therapy, including approaches that combine iontophoresis with implantable delivery systems to achieve precise chemotherapy delivery. Headquartered in Cary, North Carolina, Focal Medical emphasizes advancing treatments with targeted delivery to support quicker patient recovery and better tolerability.
Clear Labs
Venture Round in 2020
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Genalyte
Series C in 2020
Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.
Karius
Series B in 2020
Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.
Fountain Therapeutics
Series A in 2020
Founded in 2018, Fountain Therapeutics develops cellular model-based therapeutics targeting age-related diseases. It employs an AI-driven platform for identifying novel targets and potential treatments.
Lightship
Series B in 2020
Founded in 2018, Lightship aims to enhance health equity globally by transforming clinical trials. It combines digital health innovations, technology, remote care, and high-quality clinical research to make studies more accessible and offer choices, keeping patients at the core of its work.
Deep Genomics
Series B in 2020
Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.
Encellin
Seed Round in 2019
Encellin Inc., established in 2016, is a biotechnology company based in San Francisco, California. It specializes in developing innovative thin-film cell encapsulation devices for cell-based therapeutics, aiming to improve the lives of patients with chronic diseases initially focusing on Type 1 diabetes. The company's technology enables encapsulated cells to function as smart molecular factories, providing potential therapeutic solutions.
Probably Genetic
Seed Round in 2019
Probably Genetic is a company that provides genetic testing services to diagnose rare genetic conditions, including those often initially misdiagnosed as autism spectrum disorder. It enables at-home saliva sample collection and performs comprehensive DNA sequencing analysis, accompanied by personalized counseling to help patients and families obtain accurate diagnoses and access relevant clinical treatments. By offering educational materials and streamlined testing, the company aims to shorten diagnostic journeys and support individuals who fall through gaps in the healthcare system.
Pendulum Therapeutics
Series B in 2019
Pendulum Therapeutics is a biotechnology company specializing in microbiome-targeted therapies. Founded in 2013 by experts in microbiology, biochemistry, computational science, and clinical research, the company develops evidence-based medical probiotics to manage chronic illnesses, with a focus on type 2 diabetes. Its flagship product, Pendulum Glucose Control, has demonstrated efficacy in lowering blood sugar spikes and reducing A1C levels in clinical trials.
Daye
Seed Round in 2019
Founded in 2017, Daye is a London-based company dedicated to improving women's gynecological health. It manufactures and markets innovative tampon products, including CBD-infused options for period pain relief, and offers an at-home vaginal microbiome screening kit to detect infections and microbiome disruptions.
Cellino
Venture Round in 2019
Cellino develops scalable, automated biomanufacturing systems for personalized cell therapies based on induced pluripotent stem cells (iPSCs). The company aims to enable potentially curative, patient-specific treatments by producing autologous iPSCs at scale and applying AI-guided, image-driven laser processing and robotics to remove unwanted cells. By integrating image-guided machine learning, single-cell laser processing, and robotics, Cellino seeks to enhance precision, efficiency, and scalability in optical bioprocessing, accelerating the development of regenerative therapies for chronic degenerative diseases such as vision loss and Parkinson's disease.
BioAge Labs
Series B in 2019
BioAge Labs develops medicines to treat aging and age-related diseases using its proprietary BioAge platform, which combines systems biology and AI. Its pipeline includes BGE-117 for multiple aging-related conditions, BGE-175 for immune aging and respiratory infections, and azelaprag for obesity in the elderly.
Clear Labs
Series B in 2018
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Scipher Medicine
Series A in 2018
Scipher Medicine develops a molecular technology platform that predicts patient responsiveness to specific drugs in cardiovascular and autoimmune diseases. Its flagship product, PrismRA, identifies rheumatoid arthritis patients unlikely to respond to anti-TNF therapies, enabling alternative treatments. The company aims to transform drug prescription by predicting optimal therapy using simple blood samples.
Viome Life Sciences
Series B in 2018
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Clara Health
Seed Round in 2018
Clara Health operates a software platform that facilitates participation in clinical trials for patients. Its technology enables users to discover and connect with relevant trials, streamlining the process from protocol design to site selection and adherence monitoring. The platform is designed to be patient-centric, allowing individuals to filter through available trials based on their specific needs and circumstances.
Mirvie
Series A in 2018
Mirvie is a biotechnology company specializing in precise, non-invasive diagnostic tests for maternal-fetal health. Founded in 2018, the company aims to enhance pregnancy safety by providing actionable insights to families and enabling early intervention for potential complications.
Ellipsis Health
Seed Round in 2017
Founded in 2013, Ellipsis Health is a technology company that uses artificial intelligence to improve behavioral health. It analyzes patient speech and clinical data to predict health outcomes and provide real-time assessments for conditions like depression.
Eligo Bioscience
Series A in 2017
Founded in Paris, France in 2014, Eligo Bioscience specializes in developing innovative antimicrobials called Eligobiotics. These are protein-based nanodelivery vectors that employ a synthetic circuit encoding for a programmable RNA-guided nuclease, targeting bacteria based on their genome. The company's applications span therapeutics, cosmetics, biodefense, and more.
Deep Genomics
Series A in 2017
Deep Genomics is a Toronto-based company founded in 2014. It specializes in developing individualized genetic medicines using artificial intelligence systems to accelerate drug discovery and development processes, including target discovery, lead optimization, toxicity assessment, and innovative trial design. The company focuses on therapies for rare metabolic, ophthalmologic, and neurodegenerative disorders, utilizing oligonucleotide therapies that target genetic determinants of disease at the RNA or DNA level.
Karius
Series A in 2017
Karius is a life sciences company that develops genomic insights for infectious diseases. Its core offering, the Karius Test, is a non-invasive blood test that sequences microbial cell-free DNA to identify and quantify pathogens—including bacteria, DNA viruses, fungi, and parasites—for use in complicated pneumonia, infections in immunocompromised patients, and endocarditis. The company also provides laboratory services for pathogen biomarker detection for biopharmaceutical research and development. Founded in 2014, Karius is headquartered in Redwood City, California, with an additional office in Menlo Park, California. The laboratory operations are CLIA-certified and CAP-accredited, enabling high-complexity clinical testing. By mapping a patient’s microbial landscape from a single blood draw, Karius aims to support rapid, informed treatment decisions.
Viome Life Sciences
Series A in 2017
Viome Life Sciences, established in 2016 and headquartered in Bellevue, Washington, specializes in providing comprehensive health insights through its proprietary at-home clinical-grade tests. The company analyzes RNA from stool samples, along with other bodily fluids, to determine the makeup of microbial communities, offering personalized recommendations for diet and lifestyle based on the results. Viome's services aim to empower individuals to track their microbiome health, mitochondrial health, cellular health, and biological age, ultimately aiding in the prevention and reversal of chronic diseases. The company operates as a subsidiary of BlueDot LLC and sells its products through distributors and online channels.
Guardant Health
Series E in 2017
Guardant Health is a precision oncology company specializing in blood tests and analytics. It provides liquid biopsy tests like Guardant360 for advanced cancer detection, GuardantOMNI for broader gene panels, LUNAR-1 for minimal residual disease detection, and LUNAR-2 for early cancer detection. The company also offers development services to biopharmaceutical companies.
Clear Labs
Series B in 2016
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Genalyte
Series D in 2016
Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.
Siolta Therapeutics
Venture Round in 2016
Siolta Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing microbiome-based therapeutics and diagnostics aimed at preventing and treating chronic inflammatory diseases, particularly asthma and atopic conditions. Founded in 2016 and headquartered in San Francisco, California, the company utilizes its extensive understanding of the developing gut microbiome to promote immune tolerance. Siolta Therapeutics is advancing pharmaceutical-grade anaerobic organisms and is currently in phase 2 of development for its products. By leveraging insights from human microbiome studies, the company aims to create targeted microbial therapeutics and companion diagnostics that facilitate precision medicine in the management of inflammatory diseases.
Pendulum Therapeutics
Series A in 2016
Pendulum Therapeutics is a biotechnology company specializing in microbiome-targeted therapies. Founded in 2013 by experts in microbiology, biochemistry, computational science, and clinical research, the company develops evidence-based medical probiotics to manage chronic illnesses, with a focus on type 2 diabetes. Its flagship product, Pendulum Glucose Control, has demonstrated efficacy in lowering blood sugar spikes and reducing A1C levels in clinical trials.
Guardant Health
Series D in 2016
Guardant Health is a precision oncology company specializing in blood tests and analytics. It provides liquid biopsy tests like Guardant360 for advanced cancer detection, GuardantOMNI for broader gene panels, LUNAR-1 for minimal residual disease detection, and LUNAR-2 for early cancer detection. The company also offers development services to biopharmaceutical companies.
Clear Labs
Series A in 2015
Clear Labs is a biotechnology company specializing in next-generation sequencing and data analytics for infectious disease surveillance and food safety testing. Its platforms, Clear Dx™ and Clear Safety™, enable rapid identification of pathogens, supporting public health initiatives and enhancing safety across various sectors.
Genalyte
Series C in 2015
Genalyte, Inc. is a clinical and diagnostic life sciences company based in San Diego, California, that specializes in rapid diagnostic testing solutions for healthcare providers, patients, and researchers. Founded in 2007, Genalyte has developed a unique technology platform employing silicon photonic biosensors to quantify the interactions between biomolecules, such as antibodies and proteins. This innovative approach allows for the direct measurement of protein binding and nucleic acid hybridization, facilitating the monitoring of autoimmune diseases, cancer biomarker screening, and the detection of infectious agents, including Ebola. The company's Maverick platform enables rapid testing in various healthcare settings, with results typically available in under thirty minutes, thereby enhancing patient care and improving resource efficiency within the healthcare system.
Guardant Health
Series C in 2015
Guardant Health is a precision oncology company specializing in blood tests and analytics. It provides liquid biopsy tests like Guardant360 for advanced cancer detection, GuardantOMNI for broader gene panels, LUNAR-1 for minimal residual disease detection, and LUNAR-2 for early cancer detection. The company also offers development services to biopharmaceutical companies.
Guardant Health
Series B in 2014
Guardant Health is a precision oncology company specializing in blood tests and analytics. It provides liquid biopsy tests like Guardant360 for advanced cancer detection, GuardantOMNI for broader gene panels, LUNAR-1 for minimal residual disease detection, and LUNAR-2 for early cancer detection. The company also offers development services to biopharmaceutical companies.
Vivodyne
Vivodyne develops an automated robotic system that discovers life-changing drugs and cellular therapies. Its platform cultures human tissues in labs for realistic preclinical drug testing, using advanced AI to accelerate the creation of safe and effective therapeutics.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.